Pharma Executive | Expert in Medical Affairs and Drug Development | Skilled Storyteller
Medical Affairs and Clinical Development
Aligning Traditional Medical Affairs Activities with Customer Needs | Labeling development, late-stage and Phase 4 clinical development, and licensing support | Optimizing Medical Affairs Structure | Strategic planning for Medical Affairs | Targeted medical content development and communication | Training for Medical Affairs
Dr. Marina Brodsky is a pharmaceutical executive with a proven record of leadership and extensive industry experience. She is adept in in medical affairs strategies and tactics such as product launches and engaging medical community, as well as in the design and execution of clinical development programs which achieve regulatory success and meet the needs of customers. She is currently an independent consultant, providing strategic advice to small and mid-sized companies in the areas of medical affairs, drug development, and business development.
Marina retired from Pfizer Inc. in 2016 as Vice President in medical affairs after more than two decades in positions of increasing responsibility, including five years as Therapeutic Area Head (2011-2016). In that role, she led teams of scientists and physicians providing expert support for a portfolio of blockbuster Pfizer medicines such as Celebrex and Lyrica, and guiding the development of several early compounds for Alzheimer’s Disease, Parkinson’s Disease, and other neurological disorders. Prior to that role, Marina was Team Leader in medical affairs (2005-2011) and R&D (late stage development/pre-launch, 2000-2005), and a clinician/clinical team leader in early development (1995-2000). Marina has worked in several therapeutic areas including pain, neuroscience, mood disorders, addiction, and insomnia, and has co-authored papers on the use of machine learning methods to predict patient responses to treatment.
Before Pfizer, Marina was a researcher in an academic setting in Moscow, Russia, and an R&D scientist at Teva Pharmaceuticals in Israel. She received her BS from Lomonosov State University in Moscow and Kalinin State University, in Russia. She obtained her PhD in Neuroscience and Pharmacology from Weill Cornell Graduate School of Medical Sciences in New York.
Related Case Studies
Optimizing cross-functional collaboration between Medical Affairs and the Commercial organization (Marketing and Market Access)
Challenge: The Head of Medical Affairs (MA) in a midsize company was not satisfied with the level of collaboration between... read more
Understanding and anticipating the evolution (accelerated by the pandemic) of Medical Affairs priorities, strategies, activities, and methods
Challenge In 2021, a midsize Pharma company was planning to update its Medical Affairs structure and practices, in order to... read more
Generating scientific platform and customer-specific scientific narratives
Challenge: A medium size company with a novel drug in late-stage development for a neurological indication was getting behind on... read more
Consulting in Drug Development / Medical Affairs / Business Development
Advised clients on all aspects of medical affairs, from strategic planning and collaboration with commercial counterparts, to tactical implementation, metrics development, and performance assessment. Created scientific narratives for complex topics, such as novel mechanisms of action or applications of artificial intelligence. Supported business development. Developed and reviewed regulatory documents, designed drug development programs. Provided clinical and regulatory insights for using machine learning and historical databases to enhance the efficiency of clinical trials.
Vice President, Therapeutic Area Head, Neuroscience
Defined strategic direction for a portfolio of pain medicines including Lyrica, Dynastat, abuse-deterrent opioids, and compounds in development for pain and neurological disorders. Provided medical and clinical perspective for Business Development candidates' review and decisions. Lead the team through approval and launch of two novel agonist/antagonist abuse-deterrent opioids, delivered large operating plans on time and on budget.
Executive Director, Disease Area Lead, Pain
Managed a broad portfolio of analgesic medicines (as above, plus Celebrex and Flector Patch). Worked with multiple internal and external experts to develop an internally consistent and externally transparent cross-Pfizer therapeutic area strategy in support of appropriate assessment and management of patients with chronic pain.
Executive Director, Team Leader
Lead teams of scientists and physicians providing medical affairs expertise and leadership for major Pfizer brands including Chantix for smoking cessation. Lead the development of an 8,000-patient neuropsychiatric safety study of Chantix and competitors, negotiated protocol with the FDA, and set up an inter-company collaboration; the outcome of the study served as the basis for an unprecedented removal of boxed warning from the Chantix label.
Designed and implemented Phase 2/3 development programs in genitourinary & gastrointestinal therapeutic areas. Responsibilities included Business Development and Licensing evaluations in multiple therapeutic areas and with a global focus, in New York and in Tokyo, Japan, as well as the support of pre-launch planning for internal products in late-stage clinical development.